Table 4.
Multiple regression analysis’ table: probability of quality of life’s improvement or worsening: relationship between the result in the SF-36 questionnaire post-treatment and the variables.
| Multiple Regression Analysis in the General Sample | |||||
|---|---|---|---|---|---|
| Unstandardized Coefficient | Standardized Coefficients | p Value | 95.0% Confidence Interval for B | ||
| Lower Bound | Upper Bound | ||||
| Age | −0.001 | −0.001 | 0.969 | −0.034 | 0.033 |
| BMI | −0.188 | −0.053 | 0.006 | −0.320 | −0.056 |
| SF-36 pretreatment | 0.065 | 0.024 | 0.247 | −0.045 | 0.175 |
| Evolution time in years | −0.020 | −0.006 | 0.751 | −0.144 | 0.105 |
| Time disease free | −0.012 | −0.008 | 0.712 | −0.074 | 0.050 |
| DM | −5.142 | −0.054 | 0.038 | −9.990 | −0.294 |
| Other pathological | −1.444 | −0.047 | 0.025 | −2.705 | −0.182 |
| Overactive bladder | 3.357 | 0.053 | 0.023 | 0.464 | 6.250 |
| Non-repaired rectocele | 3.035 | 0.018 | 0.423 | −4.447 | 10.518 |
| Benzodiazepine | 0.619 | 0.018 | 0.520 | −1.282 | 2.520 |
| Intravesical instillation of GAG | 2.113 | 0.070 | 0.028 | 0.227 | 3.998 |
| Other pharmacological treatments | −2.104 | −0.069 | 0.038 | −4.085 | −0.123 |
| Hysterectomy | −1.272 | −0.013 | 0.670 | −7.174 | 4.629 |
| Other surgical interventions | 1.124 | 0.034 | 0.330 | −1.156 | 3.404 |
| Gynecological cancer surgery | 0.869 | 0.005 | 0.767 | −4.925 | 6.663 |
| Cesarean section | 2.253 | 0.019 | 0.546 | −5.118 | 9.624 |
| Eutocic delivery | −0.930 | −0.019 | 0.492 | −3.605 | 1.745 |
| Results | −30.580 | −0.976 | 0.0005 | −32.020 | −29.139 |
| Multiple Regression Analysis in BFB+ | |||||
| Unstandardized Coefficient | Standardized Coefficients | p-Value | 95.0% Confidence Interval for B | ||
| Lower Bound | Upper Bound | ||||
| Age | −0.042 | −0.062 | 0.186 | −0.106 | 0.022 |
| BMI | −1.013 | −0.374 | 0.00019 | −1.227 | −0.798 |
| SF-36 pretreatment | −0.777 | −0.148 | 0.003 | −1.272 | −0.282 |
| Evolution time in years | −1.325 | −0.180 | 0.000085 | −1.916 | −0.733 |
| Time disease free | −0.008 | −0.003 | 0.926 | −0.173 | 0.157 |
| DM | −0.896 | −0.017 | 0.704 | −5.677 | 3.885 |
| Other pathological | −0.623 | −0.019 | 0.555 | −2.761 | 1.515 |
| Overactive bladder | 1.312 | 0.021 | 0.720 | −6.098 | 8.723 |
| Non-repaired rectocele | 1.139 | 0.013 | 0.752 | −6.181 | 8.460 |
| Benzodiazepine | −0.475 | −0.015 | 0.821 | −4.728 | 3.778 |
| Intravesical instillation of GAG | 1.736 | 0.068 | 0.208 | −1.022 | 4.493 |
| Other pharmacological treatments | −1.645 | −0.064 | 0.322 | −4.991 | 1.701 |
| Hysterectomy | 0.836 | 0.016 | 0.704 | −3.623 | 5.294 |
| Other surgical interventions | −0.168 | −0.006 | 0.918 | −3.490 | 3.155 |
| Caesarean section | 0.627 | 0.010 | 0.856 | −6.372 | 7.625 |
| Eutocic delivery | −0.859 | −0.030 | 0.482 | −3.328 | 1.610 |
| Results | 22.524 | 0.755 | 0.00095 | 26.690 | 18.359 |
| Multiple Regression Analysis in BFB− | |||||
| Unstandardized Coefficient | Standardized Coefficients | p-Value | 95.0% Confidence Interval for B | ||
| Lower Bound | Upper Bound | ||||
| Age | −0.016 | −0.013 | 0.452 | −0.058 | 0.026 |
| BMI | 0.011 | 0.003 | 0.871 | −0.128 | 0.151 |
| SF-36 pretreatment | 0.047 | 0.018 | 0.373 | −0.058 | 0.152 |
| Evolution time in years | 0.0001 | 0.0003 | 0.998 | −0.105 | 0.104 |
| Time disease free | −0.014 | −0.005 | 0.774 | −0.108 | 0.081 |
| Other pathological | −1.839 | −0.059 | 0.003 | −3.020 | −0.659 |
| Overactive bladder | 3.559 | 0.057 | 0.007 | 1.002 | 6.116 |
| Benzodiazepine | 2.038 | 0.057 | 0.062 | −0.107 | 4.182 |
| Intravesical instillation of GAG | 2.870 | 0.087 | 0.008 | 0.780 | 4.961 |
| Other pharmacological treatments | −2.264 | −0.067 | 0.057 | −4.594 | 0.066 |
| Other surgical interventions | −0.443 | −0.012 | 0.739 | −3.088 | 2.203 |
| Gynecological cancer surgery | 0.960 | 0.007 | 0.684 | −3.738 | 5.658 |
| Results | −31.568 | −0.991 | 0.0005 | −32.842 | −30.293 |
BMI: body mass index; BFB+: group of patients who received adjuvant biofeedback of the pelvic floor; BFB−: group of patients who did not receive biofeedback of the pelvic floor. SF-36: value in the answers to the quality of life questionnaire SF-36. DM: diabetes mellitus. GAG: glycosaminoglycans. Evolution time: time of suffering from interstitial cystitis.